Irish Biotech Opsona Adds Two New Corporate VCs In $43M Series C

Irish biotech Opsona Therapeutics recently raised $43 million with the help of four corporate VCs, for use in developing its potential first-in-class product for preventing delayed graft function in high-risk renal transplant patients.